Descriptive Analysis of Pre-existing Data on Eosinophilic Esophagitis and Associated Morbidities in Cleveland Clinic Abu Dhabi, United Arab Emirates

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Feb 2

PMID 38304666

Authors

Mohamad Abuzakouk

Osama Yousef

Monica Fahmy

Zahir Chouikrat

Affiliations

Soon will be listed here.

Abstract

Background: Data on eosinophilic gastrointestinal disorders (EGIDs) are limited in the United Arab Emirates.

Objective: This study aimed to describe the distribution of eosinophilic gastritis/gastroenteritis (EoG/EGE) and eosinophilic esophagitis (EoE) among patients whose data are recorded on the Cleveland Clinic Abu Dhabi (CCAD) systems.

Methods: Anonymized aggregate data were obtained from the Clinerion Patient Network Explorer (PNEx) network installed at the CCAD on patients diagnosed with EoG/EGE (n=17, of whom 11 (64.7%) were females) or with EoE (n=118, of whom 35 (29.7%) were females) between 2015 and 2022; 63 (53.4%) were diagnosed between 2020 and 2022.

Results: The vast majority of EoE patients visited the gastroenterology clinic (111, 94.1%), followed by the primary care (70, 59.3%), the emergency medicine (60, 50.8%), and the immunology (59, 50%) units. A total of 84 patients with EoE also presented with another type-2 inflammatory condition including allergic rhinitis, food allergy, and atopic dermatitis. Proton pump inhibitors and corticosteroids were widely prescribed, and four patients with EoE have been commenced on biologics since 2020. However, heterogeneity of medication use was identified, warranting local clinical practice guidelines.

Conclusion: A referral network could be established with local and regional reach, which relies on a multidisciplinary approach for the management of EoE and associated type 2 co-morbidities. More studies are needed to better depict the clinical picture of patients with EGIDs in general and EoE, in particular, in terms of diagnosis, pharmacological treatment, non-medical interventions, disease course, and patient-reported outcomes.

References

Hui C, Hui N . A Prospective Study on the Prevalence, Extent of Disease and Outcome of Eosinophilic Gastroenteritis in Patients Presenting with Lower Abdominal Symptoms. Gut Liver. 2017; 12(3):288-296. PMC: 5945260. DOI: 10.5009/gnl17056. View

Ishimura N, Shimura S, Jiao D, Mikami H, Okimoto E, Uno G . Clinical features of eosinophilic esophagitis: differences between Asian and Western populations. J Gastroenterol Hepatol. 2015; 30 Suppl 1:71-7. DOI: 10.1111/jgh.12746. View

Chen P, Anderson L, Zhang K, Weiss G . Eosinophilic Gastritis/Gastroenteritis. Curr Gastroenterol Rep. 2021; 23(8):13. DOI: 10.1007/s11894-021-00809-2. View

Rocha R, Vitor A, Trindade E, Lima R, Tavares M, Lopes J . Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr. 2011; 170(11):1471-4. DOI: 10.1007/s00431-011-1540-4. View

van Nimwegen F, Penders J, Stobberingh E, Postma D, Koppelman G, Kerkhof M . Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J Allergy Clin Immunol. 2011; 128(5):948-55.e1-3. DOI: 10.1016/j.jaci.2011.07.027. View

Mansoor E, Saleh M, Cooper G . Prevalence of Eosinophilic Gastroenteritis and Colitis in a Population-Based Study, From 2012 to 2017. Clin Gastroenterol Hepatol. 2017; 15(11):1733-1741. DOI: 10.1016/j.cgh.2017.05.050. View

Lucendo A . Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies. Expert Rev Clin Immunol. 2019; 16(1):63-77. DOI: 10.1080/1744666X.2019.1705784. View

Chen J, Kao J . Eosinophilic esophagitis: update on management and controversies. BMJ. 2017; 359:j4482. DOI: 10.1136/bmj.j4482. View

Muir A, Wang J, Nakagawa H . Epithelial-stromal crosstalk and fibrosis in eosinophilic esophagitis. J Gastroenterol. 2018; 54(1):10-18. PMC: 6314980. DOI: 10.1007/s00535-018-1498-3. View

10.

Lucendo A, Molina-Infante J, Arias A, von Arnim U, Bredenoord A, Bussmann C . Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017; 5(3):335-358. PMC: 5415218. DOI: 10.1177/2050640616689525. View

11.

Altamimi E, Ahmad B, Abu-Aqoulah A, Rawabdeh N . Clinico-pathological characteristics of eosinophilic esophagitis in Jordanian children. Prz Gastroenterol. 2022; 17(3):207-212. PMC: 9475479. DOI: 10.5114/pg.2021.109975. View

12.

Jackson D, Akuthota P, Andradas R, Bredenoord A, Cordell A, Gray S . Improving Care in Eosinophil-Associated Diseases: A Charter. Adv Ther. 2022; 39(6):2323-2341. PMC: 9055373. DOI: 10.1007/s12325-022-02110-8. View

13.

Kapel R, Miller J, Torres C, Aksoy S, Lash R, Katzka D . Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups. Gastroenterology. 2008; 134(5):1316-21. DOI: 10.1053/j.gastro.2008.02.016. View

14.

Richter J . Eosinophilic Esophagitis Dilation in the Community--Try It--You will Like It--But Start Low and Go Slow. Am J Gastroenterol. 2016; 111(2):214-6. DOI: 10.1038/ajg.2015.433. View

15.

Wolf W, Jerath M, Sperry S, Shaheen N, Dellon E . Dietary elimination therapy is an effective option for adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014; 12(8):1272-9. PMC: 4102669. DOI: 10.1016/j.cgh.2013.12.034. View

16.

McMurray J, Clair B, Spriet S, Min S, Brooks D, Mikita C . Outcomes of eosinophilic esophagitis in patients managed in a multidisciplinary clinic. Allergy Asthma Proc. 2022; 43(1):78-84. DOI: 10.2500/aap.2022.43.210102. View

17.

Morita H, Moro K, Koyasu S . Innate lymphoid cells in allergic and nonallergic inflammation. J Allergy Clin Immunol. 2016; 138(5):1253-1264. DOI: 10.1016/j.jaci.2016.09.011. View

18.

Hasosah M, Sukkar G, Alsahafi A, Thabit A, Fakeeh M, Al-Zahrani D . Eosinophilic esophagitis in Saudi children: symptoms, histology and endoscopy results. Saudi J Gastroenterol. 2011; 17(2):119-23. PMC: 3099057. DOI: 10.4103/1319-3767.77242. View

19.

Doherty T, Baum R, Newbury R, Yang T, Dohil R, Aquino M . Group 2 innate lymphocytes (ILC2) are enriched in active eosinophilic esophagitis. J Allergy Clin Immunol. 2015; 136(3):792-794.e3. PMC: 4562810. DOI: 10.1016/j.jaci.2015.05.048. View

20.

Lee H . Changing Concept of the Prevalence of Eosinophilic Esophagitis: Visible and Hidden Patients. Clin Endosc. 2018; 51(4):307-309. PMC: 6078922. DOI: 10.5946/ce.2018.071. View